Hepatitis B e Antigen Synthesis is Inhibited by a Galactosylated Arginine-Rich Macromolecule Via Asialoglycoprotein Receptor
1. Abstract 1.1. Aims: The poor prognoses of hepatitis B virus (HBV) infection are correlated with hepatitis B e antigen (HBeAg). Current antiviral therapy does not directly interfere with HBeAg synthesis. HBeAg formation depends on proprotein convertase furin. To block HBeAg synthesis on purpose, galactosylated arginine-rich macromolecular furin inhibitors were developed and evaluated. DOI:http://dx.doi.org/10.47829/JJGH.2021.51002